This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 23:40, 20 October 2011 (Updating {{drugbox}} (changes to verified fields - updated 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 23:40, 20 October 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to verified fields - updated 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 1-3 h |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.057.046  |
| Chemical and physical data | |
| Formula | C16H21NO3 |
| Molar mass | 275.347 g/mol g·mol |
InChI
| |
| (what is this?) (verify) | |
Rolipram is a PDE4-inhibitor. Like most PDE4-inhibitors, it is an anti-inflammatory drug. Rolipram is being studied as a possible alternative to current antidepressants. Recent studies show that rolipram may have antipsychotic effects. Other beneficial effects of rolipram are:
- Improved long term memory
- Increased wakefulness
- Increased neuroprotection
Rolipram shows promise in ameliorating Alzheimer's disease, Parkinson's disease and also in the regeneration of severed spinal cord axonal bodies.
See also
References
- Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. (1993). "Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response". Inflammation. 17 (3): 333–44. doi:10.1007/BF00918994. PMID 7687237.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H. (1988). "Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives". Eur Arch Psychiatry Neurol Sci. 238 (1): 2–6. PMID 3063534.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Wachtel H. (1983). "Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors". Neuropharmacology. 22 (3): 267–72. doi:10.1016/0028-3908(83)90239-3. PMID 6302550.
- Maxwell CR, Kanes SJ, Abel T, Siegel SJ. (2004). "Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications". Neuroscience. 129 (1): 101–7. doi:10.1016/j.neuroscience.2004.07.038. PMID 15489033.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. (2006). "Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity". Neuroscience. 144 (1): 239–46. doi:10.1016/j.neuroscience.2006.09.026. PMID 17081698.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E. (1998). "Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory". Proceedings of the National Academy of Science of the USA. 95 (25): 15020–5. doi:10.1073/pnas.95.25.15020. PMC 24568. PMID 9844008.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Lelkes Z, Alföldi P, Erdos A, Benedek G. (1998). "Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats". Pharmacology, Biochemistry and Behaviour. 60 (4): 835–9. doi:10.1016/S0091-3057(98)00038-0. PMID 9700966.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Block F, Schmidt W, Nolden-Koch M, Schwarz M. (2001). "Rolipram reduces excitotoxic neuronal damage". Neuroreport. 12 (7): 1507–11. doi:10.1097/00001756-200105250-00041. PMID 11388438.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Chen RW, Williams AJ, Liao Z, Yao C, Tortella FC, Dave JR. (2007). "Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation". Neuroscience Letters. 418 (2): 165–9. doi:10.1016/j.neulet.2007.03.033. PMID 17398001.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Smith, Donna L (September 14, 2009). "Reversal of long-term dendritic spine alterations in Alzheimer disease models". Proceedings of the National Academy of Sciences of the United States. 106 (39): 16877–16882. doi:10.1073/pnas.0908706106. PMC 2743726. PMID 19805389. Retrieved 2009-11-13.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help) - MF, Beal (2005). "Oxidative Damage in Parkinson's Disease". U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012. Retrieved 2009-11-13.
{{cite web}}: Unknown parameter|coauthors=ignored (|author=suggested) (help) - Nikulina, E. (June 8, 2004). "The Phosphodiesterase Inhibitor Rolipram Delivered after a Spinal Cord Lesion Promotes Axonal Regeneration and Functional Recovery". Proceedings of the National Academy of Sciences of the United States. 101: 8786. doi:10.1073/pnas.0402595101. JSTOR 3372336.